MariMed Reports First Quarter 2024 Earnings

Rhea-AI Summary

MariMed Inc. reported strong financial results for the first quarter of 2024, with revenue reaching $37.9 million and a positive adjusted EBITDA for the 17th consecutive quarter. The company outperformed its competition in all markets, including Illinois, with significant growth in its wholesale business. MariMed also announced key operational highlights, such as expanding its branded products in Illinois, opening a new dispensary in Maryland, and forming partnerships with Boston music venues. The company's 2024 financial targets include revenue growth of 5-7% and non-GAAP Adjusted EBITDA growth of 0-2%.

Positive

• MariMed Inc. reported a revenue increase to $37.9 million for the first quarter of 2024.

• The company achieved a positive adjusted EBITDA for the 17th consecutive quarter.

• MariMed outperformed its competition in all markets, including Illinois, indicating strong growth in its wholesale business.

• The company expanded its branded products in Illinois and opened a new dispensary in Maryland, enhancing its operational footprint.

• MariMed formed partnerships with iconic Boston music venues, boosting its brand exposure and consumer outreach.

• The company's 2024 financial targets project revenue growth of 5-7% and non-GAAP Adjusted EBITDA growth of 0-2%, showcasing a positive outlook for the year.

Negative

• MariMed reported a decrease in GAAP gross margin from 45% in 2023 to 43% in the first quarter of 2024.

• The company experienced a decline in non-GAAP gross margin from 46% in 2023 to 44% in the first quarter of 2024.

• MariMed incurred a GAAP net loss of $1.3 million in the first quarter of 2024, compared to a net loss of $0.7 million in the same period in 2023.

• The company reported a non-GAAP net loss of $0.6 million in the first quarter of 2024, contrasting with a net income of $0.3 million in the prior year.

• MariMed's non-GAAP Adjusted EBITDA declined to $4.7 million in the first quarter of 2024, down from $7.1 million in the same period in 2023.

• The non-GAAP Adjusted EBITDA margin decreased from 21% in 2023 to 12% in the first quarter of 2024, signaling a negative trend in profitability.

NORWOOD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the first quarter ended March 31, 2024.

“With the first quarter now in the books, I’m pleased to say we are on track with our strategic plan and financial targets,” said Jon Levine, Chief Executive Officer. “The tremendous growth in our wholesale business was undoubtedly the highlight of the quarter. I am proud that once again, MariMed outperformed our competition in every market in which we operate, including Illinois. The strong revenue growth led to our 17th consecutive quarter of positive adjusted EBITDA.”

Financial Highlights¹

The following table summarizes the Company's consolidated financial highlights (in millions, except percentage amounts):

	Three months ended March 31,
		2024				2023
Revenue	$	37.9			$	34.4
GAAP Gross margin		43	%			45	%
Non-GAAP Gross margin		44	%			46	%
GAAP Net loss	$	(1.3	)		$	(0.7	)
Non-GAAP Net (loss) income	$	(0.6	)		$	0.3
Non-GAAP Adjusted EBITDA	$	4.7			$	7.1
Non-GAAP Adjusted EBITDA margin		12	%			21	%

¹ See the reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures and additional information about non-GAAP measures in the section entitled “Discussion of Non-GAAP Financial Measures” below and in the financials information included herewith.

CONFERENCE CALL

MariMed management will host a conference call on Thursday, May 9, 2024 at 8:00 a.m. Eastern time, to discuss these results. The conference call may be accessed through MariMed’s Investor Relations website, or by clicking the following link: MRMD Q124 Earnings Webcast.

FIRST QUARTER 2024 OPERATIONAL HIGHLIGHTS

During the first quarter, the Company announced the following developments in the implementation of its strategic growth plan:

• January 2: MariMed began selling its award-winning branded products through the Company's new wholesale business in Illinois. MariMed's brands, including Betty's Eddies, Bubby's Baked, Vibations, and InHouse are now widely available in 135 dispensaries throughout the state.
• February 26: Thrive Dispensary Casey, the adult-use dispensary MariMed managed since opening in Fall 2023, received its Certificate of Occupancy from the Illinois Cannabis Control Commission to commence operations in its permanent brick-and-mortar facility. The Company subsequently transitioned from its temporary facility and commenced operations in the new facility in March 2024.
• March 6: MariMed announced the expansion of its Maryland footprint with the acquisition of its second dispensary in the state. On February 1, the Company entered into a definitive agreement to acquire the operating assets of Our Community Wellness & Compassionate Care Center, Inc, a medical licensed dispensary operator. The Company subsequently announced the closing of the acquisition on April 9, and plans to open the dispensary, which is located in Upper Marlboro, and commence adult-use sales upon regulatory approval.
  

OTHER DEVELOPMENTS

Subsequent to the end of the first quarter, the Company announced the following further developments:

• April 10: MariMed announced a partnership with two iconic Boston music venues, MGM Music Hall Fenway and Citizens House of Blues Boston. This groundbreaking partnership positions Nature’s Heritage as the exclusive cannabis sponsor at each venue. The brand will receive over one million consumer impressions resulting from onsite fan experiences, in-venue advertising, and digital advertising.
• April 11: MariMed announced the closing of its acquisition of Thrive Dispensary in Casey, Illinois. The approval of the license transfer by the Illinois Department of Financial & Professional Regulation, and subsequent closing of the acquisition, allows MariMed to fully consolidate the financial results of this dispensary, which had previously been operated under a Managed Services Agreement.

2024 FINANCIAL GUIDANCE

MariMed's full year 2024 financial targets are based on organic growth of its existing operating assets and do not include new revenue-generating projects requiring regulatory approvals. The Company believes this conservative approach to offering financial targets allows investors and analysts to focus on key operating milestones versus discussions around issues outside the Company's control. As such, the Company's full year 2024 financial targets remain at:

• Revenue growth of 5% to 7%;
• Non-GAAP Adjusted EBITDA growth of 0% to 2%;
• Capital expenditures of $10 million.
  

DISCUSSION OF NON-GAAP FINANCIAL MEASURES

MariMed’s management uses several different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of its business, making operating decisions, and planning and forecasting future periods. The Company has provided in this release several non-GAAP financial measures: Non-GAAP Gross margin, Non-GAAP Net income (loss), Non-GAAP Adjusted EBITDA and non-GAAP Adjusted EBITDA margin, as supplements to Revenue, Gross margin, Net income (loss) and other financial measures prepared in accordance with GAAP.

Management believes these non-GAAP financial measures are useful in reviewing and assessing the performance of the Company, and when planning and forecasting future periods, as they provide meaningful operating results by excluding the effects of expenses that are not reflective of its operating business performance. In addition, the Company’s management uses these non-GAAP financial measures to understand and compare operating results across accounting periods and for financial and operational decision-making. The presentation of these non-GAAP measures is not intended to be considered in isolation or as a substitute for the financial information prepared in accordance with GAAP.

Management believes that investors and analysts benefit from considering non-GAAP financial measures in assessing the Company’s financial results and its ongoing business, as it allows for meaningful comparisons and analysis of trends in the business. In particular, non-GAAP adjusted EBITDA is used by many investors and analysts themselves, along with other metrics, to compare financial results across accounting periods and to those of peer companies.

As there are no standardized methods of calculating non-GAAP financial measures, the Company’s calculations may differ from those used by analysts, investors and other companies, even those within the cannabis industry, and therefore may not be directly comparable to similarly titled measures used by others.

Management defines non-GAAP Adjusted EBITDA as income (loss) from operations, determined in accordance with GAAP, excluding the following items:

• depreciation of fixed assets;
• amortization of acquired intangible assets;
• Impairment or write-downs of intangible assets;
• stock-based compensation;
• legal settlements; and
• acquisition-related and other expenses.

For further information, please refer to the publicly available financial filings available on MariMed's Investor Relations website, as filed with the U.S. Securities and Exchange Commission, or as filed with the Canadian securities regulatory authorities on the SEDAR website.

ABOUT MARIMED

MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including Betty’s Eddies, Nature’s Heritage, InHouse, Bubby’s Baked, K Fusion, Kalm Fusion, and Vibations, which are trademarks of MariMed Inc. For additional information, visit www.marimedinc.com. 

IMPORTANT CAUTION REGARDING FORWARD-LOOKING STATEMENTS:

The information in this release contains “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, which are subject to several risks and uncertainties.   All statements other than statements of historical facts contained in this release, including without limitation statements regarding projected financial results for 2024, including management’s belief that it will report its fifth consecutive year of positive operating cash flow, anticipated openings of dispensaries and facilities, timing of regulatory approvals, plans and objectives of management for future operations, are forward-looking statements.   Without limiting the foregoing, the words “anticipates”, “believes”, “estimates”, “expects”, “expectations”, “intends”, “may”, “plans”, and other similar language, whether in the negative or affirmative, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based on our current beliefs and assumptions regarding our business, timing of regulatory approvals, the ability to obtain new licenses, business prospects and strategic growth plan, and other future conditions.   Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict.   Our actual results may differ materially from those contemplated in these forward-looking statements due to various risks, uncertainties, and other important factors, including, among others, reductions in customer spending, our ability to recruit and retain key personnel, and disruptions from the integration efforts of acquired companies.

These factors are not intended to be an all-encompassing list of risks and uncertainties that may affect our business and results of operations.   These statements are not a guarantee of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company’s services and products, changes in the law and its enforcement, and changes in the economic environment. Additional information regarding these and other factors can be found in our reports filed with the U.S. Securities and Exchange Commission.   In providing these forward-looking statements, the Company expressly disclaims any obligation to update these statements publicly or otherwise, whether as a result of new information, future events or otherwise, except as required by law.

All trademarks and service marks are the property of their respective owners.

For More Information Contact:

Investor Relations:
Steve West, Vice President, Investor Relations
Email: ir@marimedinc.com 
Phone: (781) 277-0007

Company Contact:
Howard Schacter, Chief Communications Officer
Email: hschacter@marimedinc.com 
Phone: (781) 277-0007

MariMed Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)

	March 31, 2024				December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	15,234			$	14,645
Accounts receivable, net		6,491				7,199
Inventory		29,044				25,306
Deferred rents receivable		612				630
Notes receivable, current portion		52				52
Investments, current portion		—				88
Due from related parties		181				105
Other current assets		3,281				3,407
Total current assets		54,895				51,432
Property and equipment, net		90,765				89,103
Intangible assets, net		12,819				17,012
Goodwill		15,812				11,993
Investments, net of current portion		274				221
Notes receivable, net of current portion		814				814
Operating lease right-of-use assets		9,456				9,716
Finance lease right-of-use assets		3,539				3,295
Other assets		12,958				12,537
Total assets	$	201,332			$	196,123
Liabilities, mezzanine equity and stockholders’ equity
Current liabilities:
Mortgages and notes payable, current portion	$	1,057			$	723
Accounts payable		10,256				9,001
Accrued expenses and other		4,613				3,549
Income taxes payable		16,271				14,434
Operating lease liabilities, current portion		1,955				1,945
Finance lease liabilities, current portion		1,303				1,210
Total current liabilities		35,455				30,862
Mortgages and notes payable, net of current portion		67,448				65,652
Operating lease liabilities, net of current portion		8,218				8,455
Finance lease liabilities, net of current portion		2,290				2,140
Other liabilities		100				100
Total liabilities		113,511				107,209
Commitments and contingencies
Mezzanine equity
Series B convertible preferred stock		14,725				14,725
Series C convertible preferred stock		4,275				4,275
Total mezzanine equity		19,000				19,000
Stockholders’ equity
Common stock		375				375
Additional paid-in capital		171,389				171,144
Accumulated deficit		(101,253	)			(99,955	)
Noncontrolling interests		(1,690	)			(1,650	)
Total stockholders’ equity		68,821				69,914
Total liabilities, mezzanine equity and stockholders’ equity	$	201,332			$	196,123

MariMed Inc.
Condensed Consolidated Statements of Operations
(in thousands, except percentages and per share amounts)
(unaudited)

	Three months ended
	March 31,
		2024				2023
Revenue	$	37,933			$	34,380
Cost of revenue		21,461				18,992
Gross profit		16,472				15,388
Gross margin		43.4	%			44.8	%
Operating expenses:
Personnel		6,465				4,656
Marketing and promotion		1,762				1,146
General and administrative		6,140				4,305
Acquisition-related and other		84				190
Bad debt		—				(44	)
Total operating expenses		14,451				10,253
Income from operations		2,021				5,135
Interest and other (expense) income:
Interest expense		(1,629	)			(2,505	)
Interest income		26				99
Other expense, net		(20	)			(900	)
Total interest and other expense, net		(1,623	)			(3,306	)
Income before income taxes		398				1,829
Provision for income taxes		1,690				2,493
Net loss		(1,292	)			(664	)
Less: Net income (loss) attributable to noncontrolling interests		6				(19	)
Net loss attributable to common stockholders	$	(1,298	)		$	(645	)
Net loss per share attributable to common stockholders:
Basic	$	(0.00	)		$	(0.00	)
Diluted	$	(0.00	)		$	(0.00	)
Weighted average common shares outstanding:
Basic		375,211				342,794
Diluted		375,211				342,794

MariMed Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

	Three months ended
	March 31,
		2024				2023
Cash flows from operating activities:
Net loss attributable to common stockholders	$	(1,298	)		$	(645	)
Net income (loss) attributable to noncontrolling interests		6				(19	)
Adjustments to reconcile net income (loss) to cash provided by operating activities:
Depreciation and amortization of property and equipment		1,938				986
Amortization of intangible assets		374				557
Stock-based compensation		244				208
Amortization of original debt issuance discount		—				55
Amortization of debt discount		87				328
Amortization of debt issuance costs		18				—
Payment-in-kind interest		14				118
Present value adjustment of notes payable		—				719
Bad debt income		—				(44	)
Obligations settled with common stock		1				1
Write-off of disposed assets		1				906
Gain on finance lease adjustment		—				(13	)
Loss on changes in fair value of investments		121				20
Changes in operating assets and liabilities:
Accounts receivable, net		707				(132	)
Deferred rents receivable		18				18
Inventory		(3,738	)			(3,246	)
Other current assets		391				639
Other assets		63				19
Accounts payable		1,334				(1,961	)
Accrued expenses and other		1,091				(207	)
Income taxes payable		1,838				(2,806	)
Net cash provided by (used in) operating activities		3,210				(4,499	)
Cash flows from investing activities:
Purchases of property and equipment		(3,368	)			(3,052	)
Business acquisitions, net of cash acquired		—				(2,995	)
Advances toward future business acquisitions		(485	)			(300	)
Purchases of investments		(86	)			—
Purchases of cannabis licenses		(265	)			(601	)
Proceeds from notes receivable		13				43
Due from related party		(75	)			(20	)
Net cash used in investing activities		(4,266	)			(6,925	)
Cash flows from financing activities:
Proceeds from term loan		—				29,100
Proceeds from Construction to Permanent Commercial Real Estate Mortgage Loan		1,047				—
Proceeds from mortgages		1,163				—
Principal payments of mortgages		(65	)			(203	)
Principal payments of promissory notes		(135	)			(9	)
Repayment and retirement of promissory notes		—				(5,503	)
Principal payments of finance leases		(320	)			(69	)
Distributions		(45	)			(34	)
Net cash provided by financing activities		1,645				23,282
Net increase in cash and cash equivalents		589				11,858
Cash and equivalents, beginning of year		14,645				9,737
Cash and cash equivalents, end of period	$	15,234			$	21,595

MariMed Inc.
Reconciliation of Non-GAAP and GAAP Financial Measures
(in thousands, except percentages)
(unaudited)

	Three months ended
	March 31,
		2024				2023
Non-GAAP Adjusted EBITDA
GAAP Income from operations	$	2,021			$	5,135
Depreciation and amortization of property and equipment		1,938				986
Amortization of acquired intangible assets		374				557
Stock-based compensation		244				206
Acquisition-related and other		84				190
Adjusted EBITDA	$	4,661			$	7,074
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)
GAAP Income from operations		5.3	%			14.9	%
Depreciation and amortization of property and equipment		5.2	%			2.9	%
Amortization of acquired intangible assets		1.0	%			1.6	%
Stock-based compensation		0.6	%			0.6	%
Acquisition-related and other		0.2	%			0.6	%
Adjusted EBITDA margin		12.3	%			20.6	%

GAAP Gross margin	43.4	%		44.8	%
Amortization of acquired intangible assets	0.4	%		0.8	%
Non-GAAP Gross margin	43.8	%		45.6	%

GAAP Net loss	$	(1,292	)		$	(664	)
Amortization of acquired intangible assets		374				557
Stock-based compensation		244				206
Acquisition-related and other		84				190
Non-GAAP Net (loss) income	$	(590	)		$	289

MariMed Inc.
Supplemental Information
Revenue Components
(in thousands)
(unaudited)

	Three months ended
	March 31,
		2024			2023
Product revenue:
Product revenue - retail		22,346			23,183
Product revenue - wholesale		14,505			10,376
Total product revenue		36,851			33,559
Other revenue		1,082			821
Total revenue	$	37,933		$	34,380

FAQ

<p>What were MariMed's revenue figures for the first quarter of 2024?</p>

MariMed reported a revenue of $37.9 million for the first quarter of 2024.

<p>How did MariMed perform in terms of adjusted EBITDA for the first quarter of 2024?</p>

MariMed achieved a positive adjusted EBITDA for the 17th consecutive quarter in the first quarter of 2024.

<p>What are MariMed's 2024 financial targets?</p>

MariMed's 2024 financial targets include revenue growth of 5-7% and non-GAAP Adjusted EBITDA growth of 0-2%.

<p>What operational highlights did MariMed announce for the first quarter of 2024?</p>

MariMed expanded its branded products in Illinois, opened a new dispensary in Maryland, and formed partnerships with Boston music venues in the first quarter of 2024.

<p>What were the key financial metrics that declined for MariMed in the first quarter of 2024?</p>

MariMed experienced declines in GAAP gross margin, non-GAAP gross margin, GAAP net loss, non-GAAP net loss, non-GAAP Adjusted EBITDA, and the non-GAAP Adjusted EBITDA margin in the first quarter of 2024.